Skip to main content

Advertisement

Table 1 Clinico-pathological features of the analyzed patients

From: Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Characteristic Age [Years]  
Median age at diagnosis 61.6  
Range [Min.-Max.] 40.2 - 79.9  
Patients with temozolomide therapy   
  Median age at diagnosis 59.2  
Patients without temozolomide therapy   
  Median age at diagnosis 64.0  
Characteristic Number of patients % of patients
Age classes   
  <50 years 11 17.2
  50 - 60 years 18 28.1
  60 - 70 years 20 31.3
  >70 years 15 23.4
Sex   
  Male 39 60.9
  Female 25 39.1
Pathohistology   
  Glioblastoma multiforme 64  
  Relapses of primary glioblastoma multiforme 17  
Therapy   
  Only Radiotherapy 11 17.2
  Radiotherapy and temozolomide 45 70.3
  No adjuvant therapy 6 9.4
  No therapy data applicable 2 3.1
Overall survival (OS)   
  Median [Days] 459  
  Range [Min.-Max.] 34 - 1954  
  1-year survival 38 59.4
  2-year survival 9 14.1
OS of patients with temozolomide therapy   
  Median [Days] 515
  Range [Min.-Max.] 95 - 1954
OS of patients without temozolomide therapy  
  Median [Days] 87
  Range [Min.-Max.] 34 - 701
Vital status at study end (30.06.2009)   
  Dead 47 73.4
  Alive 17 26.6